Drs. Jeffrey Lieberman, M.D. and David Sinclair, Ph.D. to Present ‘The New Frontier of Longevity Science: Living Well Beyond Your Years’ at SXSW 2025
March 07, 2025 17:09 ET
|
Dr. Jeffrey Lieberman
Drs. David Sinclair & Jeffrey Lieberman to explore the latest advances in longevity science and emerging new model for living better, longer at SXSW 2025
DTC Genetic Testing Market Set to Grow at 10% CAGR Through 2029
February 27, 2025 04:43 ET
|
BCC Research LLC
Boston, Feb. 27, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the demand for Direct-to-Consumer Genetic Testing: Global Markets and Technologies is expected to grow from...
YourUpdateTV Speaks with Mathew Knowles and Ruth Tennen from 23andMe to Discuss Genetic Risk Factors for Cancer
February 24, 2025 11:01 ET
|
D S Simon
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- February is Cancer Prevention Month, and the perfect opportunity to highlight the importance of genetic testing in understanding cancer risk factors....
Digbi Health Expands its Multi-Condition Care Platform to Enhance Efficacy and Adherence to GLP-1 Drugs
January 17, 2025 05:21 ET
|
Digbi Health
PALO ALTO, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Digbi Health, a pioneer in Precision Biology, is advancing obesity management with groundbreaking enhancements to GLP-Compass (™), its...
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
January 13, 2025 06:05 ET
|
Regeneron Pharmaceuticals, Inc.
The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers)...
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
December 09, 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer.
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
November 20, 2024 16:30 ET
|
Myriad Genetics, Inc.
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2.
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
November 13, 2024 08:00 ET
|
Myriad Genetics, Inc.
Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations.
One of the Largest and Most Diverse Studies on Sickle Cell Trait and Blood Clots Reveals Findings That Impact All Populations
September 12, 2024 16:05 ET
|
23andMe, Inc.
SUNNYVALE, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, in collaboration with lead researchers at...
Biongevity Enhances Longevity Strategy with Harish Consul as Chief Venture Capital Advisor
September 04, 2024 09:49 ET
|
BioAro
Biongevity appoints Harish Consul as Chief Venture Capital Advisor, accelerating global growth with innovative precision health and longevity strategies.